Group 1: Product Development and Market Competitiveness - The new generation of high-end bone-integrated implants is expected to complete product registration within this year, significantly enhancing the company's market competitiveness in the oral field [1][2] - The product features hydrophilic sandblasting and acid washing surface treatment to increase bone integration strength, improving adaptability and stability for different bone conditions [2][3] Group 2: Financial Performance - Revenue from other products increased from 9 million to 16 million, a growth of 700 thousand, with 330 thousand attributed to the PEEK material sternum fixation belt [3] - The increase in revenue also includes contributions from maxillofacial repair products and supporting surgical tools [3]

Financial Performance - The company achieved a revenue of CNY 153.34 million in the first half of 2024, representing a year-on-year growth of 13.48% [4] - The net profit attributable to shareholders was CNY 48.79 million, an increase of 24.53% compared to the same period last year [4] - The net profit after deducting non-recurring gains and losses was CNY 40.30 million, up by 7.35% year-on-year [5] Business Segments - Neurosurgery business generated revenue of CNY 133.06 million, with a year-on-year growth of 7.97%. PEEK material products contributed CNY 96.22 million, growing by 15.45% and accounting for 65.10% of the main business revenue [5] - The cardiothoracic surgery segment reported revenue of CNY 9.84 million, with PEEK material chest fixation products achieving sales of CNY 9.74 million, a significant increase of 51.53% [5] Market Expansion - The company successfully implemented the Henan Provincial Alliance neurosurgery centralized procurement in Q2 2024, leading to increased penetration of PEEK material products [6] - In the first half of 2024, overseas revenue reached CNY 16.22 million, a growth of 14.97% year-on-year, with the overseas subsidiary BIOPLATE generating CNY 15.03 million, up by 18.53% [8] Product Development - The company is actively expanding its jaw repair business, leveraging academic training and partnerships with experts to enhance market recognition and application [7] - The introduction of the new generation "high-end bone integration implants and accessories" is in the product registration phase, expected to enhance market competitiveness in the dental field [10] Innovation and Future Strategy - The innovative product "3D printed PEEK cranial system" has been successfully applied in multiple surgeries, demonstrating its superior performance and accelerating the commercialization of innovative technologies [10] - The company plans to continue expanding its high-value non-centralized procurement products and optimize production processes to maintain stable gross margins [6]

Summary of the Conference Call for 康托医疗 Company Overview - 康托医疗 specializes in three categories of medical devices, primarily focusing on neurosurgery and repair fields [1] Key Points and Arguments - The company is set to discuss its mid-year performance for 2024, indicating a focus on financial results and operational metrics [1] - The management, represented by the Secretary of the Board, emphasizes the importance of understanding the basic situation of the mid-year report [1] Additional Important Content - The call highlights the company's commitment to providing insights into its performance, which may include revenue figures, market share, and growth strategies in the medical device sector [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported revenue of 153 million yuan for H1 2024, representing a year-over-year increase of 13.48%, and a net profit of 49 million yuan, up 24.53% year-over-year. In Q2 2024, revenue reached 83 million yuan, a year-over-year increase of 18.36%, with net profit at 29 million yuan, up 46.04% year-over-year [2][3] - The company is actively adjusting its business strategy to enhance product penetration and accelerate product admission into hospitals, particularly in lower-tier markets, contributing to steady revenue growth [2] - The gross margin for H1 2024 was 80.10%, a decrease of 0.98 percentage points, while the net margin increased by 2.93 percentage points to 31.48% [2] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 90 million, 113 million, and 141 million yuan respectively, with corresponding EPS of 1.11, 1.39, and 1.73 yuan, leading to P/E ratios of 16.9, 13.5, and 10.8 times [2][3] Summary by Sections Financial Performance - H1 2024 revenue was 153 million yuan, with a year-over-year growth of 13.48% - Net profit for H1 2024 was 49 million yuan, reflecting a year-over-year increase of 24.53% - Q2 2024 revenue was 83 million yuan, up 18.36% year-over-year, and net profit was 29 million yuan, up 46.04% year-over-year [2][3] Product Performance - PEEK neurosurgical products generated revenue of 96 million yuan, a year-over-year increase of 15.45%, with a gross margin of 84.86% - The penetration rate for PEEK cranial repair products was approximately 13.59%, indicating significant growth potential in the industry [2] - PEEK sternal fixation strips achieved revenue of 974 thousand yuan, growing by 52%, with substantial market potential [2] R&D and Market Expansion - The company is expanding its product offerings and enhancing R&D efforts, including local production of PEEK plates in the U.S. and advancing the registration of new products in China [2] - The company is also focusing on comprehensive solutions in the dental sector through its "Yizhi" brand, which includes a range of dental products [2]

证券代码：688314 证券简称：康拓医疗 公告编号：2024-022 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理，并与保荐机构、募集 资金专户监管银行签订了募集资金三方监管协议。 （二）2024 年半年度（或"报告期"）募集资金使用金额及期末余额 截至 2024 年 6 月 30 日，公司累计使用募集资金 205,867,006.66 元，2024 年 上半 ...

关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688314 证券简称：康拓医疗 公告编号：2024-023 西安康拓医疗技术股份有限公司 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 15 日(星期四)至 08 月 21 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2024 年 8 月 14 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 08 月 22 日下午 16:00-17:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度的经营 成果 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2024-021 西安康拓医疗技术股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安康拓医疗技术股份有限公司(以下简称"公司")第二届监事会第九次会 议于 2024 年 8 月 12 日在公司会议室以现场的方式召开，会议通知已于 2024 年 8 月 2 日通过邮件的方式送达全体监事。本次会议由监事会主席帖凯先生主持， 会议应出席监事 3 人，实际出席监事 3 人。会议召开符合《中华人民共和国公司 法》《上海证券交易所科创板股票上市规则》等有关法律、行政法规、部门规章、 规范性文件和《西安康拓医疗技术股份有限公司章程》的规定，会议召开合法、 有效。 二、监事会会议审议情况 经与会监事审议表决，形成会议决议如下: （一）审议通过《关于公司 2024 年半年度报告及摘要的议案》 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 经审核，监事会认为：公司 2024 年半年度报告及其摘要的编制和审核程序 符合法律、行政法 ...

国浩律师(西安)事务所 专项核查意见 国浩律师(西安)事务所 关 于 西安康拓医疗技术股份有限公司 控股股东、实际控制人、董事长增持公司股份 的 专项核查意见 國浩律師（西安）事務所 GRANDALL LAW FIRM(XI'AN) 致:西安康拓医疗技术股份有限公司 国浩律师(西安)事务所(以下简称"本所")接受西安康拓医疗技术有限公司 (以下简称"康拓医疗"或者"公司")的委托,就公司控股股东、实际控制人、 董事长胡立人先生增持康拓医疗股份事宜(以下简称"本次增持")的相关事宜出 具本专项核查意见。 本所及经办律师依据《中华人民共和国公司法》(以下简称"《公司 法》"）、《中华人民共和国证券法》(以下简称"《证券法》")、《上市公司 收购管理办法》(以下简称"《收购管理办法》")、《上海证券交易所上市公司 自律监管指引第8号—股份变动管理》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本专项核查意见出具目以前已经 发生或者存在的事实,严格履行了法定职责,遵循了勤勉尽责和诚实信用原则,进 行了充分的核查验证,保证本专项核查意见所认定的事实真实、准确、完整,所发 表的结论 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2024-020 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 西安康拓医疗技术股份有限公司（以下简称"公司"）于 2024 年 6 月 7 日 收到公司董事、总经理朱海龙先生出具的《增持股份告知函》，朱海龙先生基于 对公司未来持续稳定发展的坚定信心及对公司长期价值的高度认可，以个人自 有资金通过上海证券交易所交易系统集中竞价交易方式增持公司股份 20,000 股， 占公司总股本的 0.02%。现将有关情况公告如下： 一、本次增持情况说明 1、增持主体：公司董事、总经理朱海龙先生。 2、增持目的：基于对公司未来持续稳定发展的坚定信心及对公司长期价值 的高度认可。 3、增持方式：集中竞价交易。 4、资金来源：自有资金。 5、本次增持的具体情况： 币种：人民币 | 增持 | 增持 | 增持 | | | | 成交均价 | 增持数量 | 交易金 额（万 | 占公司总 股本比例 | | --- | --- | --- | --- | --- | --- | --- ...

证券代码：688314 证券简称：康拓医疗 公告编号：2024-019 西安康拓医疗技术股份有限公司 关于公司控股股东、实际控制人增持股份的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承 担法律责任。 西安康拓医疗技术股份有限公司（以下简称"公司"）于 2024 年 6 月 7 日 收到控股股东、实际控制人、董事长胡立人先生出具的《增持股份告知函》，胡 立人先生基于对公司未来持续稳定发展的坚定信心及对公司长期价值的高度认 可，以个人自有资金通过上海证券交易所交易系统集中竞价交易方式增持公司 股份 110,000 股，占公司总股本的 0.14%。现将有关情况公告如下： 一、本次增持情况说明 1、增持主体：公司控股股东、实际控制人、董事长胡立人先生。 股份 3,808,000 股，胡立人先生直接持有及间接控制公司股份合计 43,243,788 股， 占公司总股本的 53.23%。本次增持完成后，胡立人先生直接持有及间接控制公 司股份合计 43,353,788 股，占公司总股本的 53.37%。 7、本次增持主体暂未提出后续 ...